Shasun Pharmaceuticals fell 4.48% to Rs 156.60 at 12:00 IST on BSE on profit booking after the stock jumped 37.08% in the preceding six trading sessions to Rs 163.95 on 9 May 2014, from a recent low of Rs 119.60 on 30 April 2014.
Meanwhile, the BSE Sensex was up 397.01 points, or 1.73%, to 23,391.24.
On BSE, so far 1.44 lakh shares were traded in the counter, compared with an average volume of 2.74 lakh shares in the past one quarter.
The stock hit a high of Rs 166.45 and a low of Rs 156.10 so far during the day. The stock hit a 52-week high of Rs 168.50 on 9 May 2014. The stock hit a 52-week low of Rs 45.60 on 26 June 2013.
The stock had outperformed the market over the past one month till 9 May 2014, rising 94.60% compared with 1.29% rise in the Sensex. The scrip had also outperformed the market in past one quarter, soaring 108.72% as against Sensex's 12.85% rise.
The small-cap company has an equity capital of Rs 11.32 crore. Face value per share is Rs 2.
On 7 May 2014, Morgan Stanley Asia (Singapore) PTE acquired 4.02 lakh equity shares, or 0.71% equity, of Shasun Pharmaceuticals at Rs 146.86 per share on NSE.
On a consolidated basis, Shasun Pharmaceuticals' net profit rose 58.8% to Rs 13.04 crore on 20.3% increase in net sales to Rs 309.38 crore in Q3 December 2013 over Q3 December 2012.
Shasun Pharmaceuticals is an integrated pharmaceutical company head office in Chennai India with locations in India, UK and USA. Shasun's unique technologies and reliable GMP compliant facilities provide high quality products. Partnering with global pharmaceutical and retail companies, Shasun provides wide range of OTC and Rx Products and services.
Powered by Capital Market - Live News
